ANGEL2: A Potential Drug Target and Biomarker for the Treatment of Neurodegenerative Diseases

Target Name: ANGEL2

NCBI ID: G90806

ANGEL2

ANGEL2: A Potential Drug Target and Biomarker for the Treatment of Neurodegenerative Diseases

Neurodegenerative diseases are a group of disorders that affect the nervous system and can result in progressive cognitive and behavioral decline. These diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, and other forms of dementia. Current treatments for these diseases are limited and often have significant side effects. Therefore, there is a need for new and better treatments that can slow the progression of these diseases and improve quality of life.

One potential solution to this problem is ANGEL2, a protein that has been identified as a potential drug target and biomarker for the treatment of neurodegenerative diseases. ANGEL2 is a transmembrane protein that is expressed in many different tissues and cells in the body. It is involved in a variety of cellular processes, including cell signaling, migration, and invasion.

Recent studies have suggested that ANGEL2 may be a drug target for neurodegenerative diseases because it is involved in the development and progression of these diseases. For example, studies have shown that ANGEL2 is involved in the development of neurodegeneration in models of Alzheimer's disease and Parkinson's disease. Additionally, ANGEL2 has been shown to be overexpressed in the brains of people with Alzheimer's disease, which may indicate that it is a potential drug target for this disease.

ANGEL2 may also be a biomarker for neurodegenerative diseases. This is because it is a protein that is expressed in many different tissues and cells in the body, which means that it may be a useful indicator of the presence of these diseases. For example, ANGEL2 has been shown to be downregulated in the brains of people with Alzheimer's disease, which may indicate that it is a potential biomarker for this disease.

In addition to its potential drug target and biomarker properties, ANGEL2 is also a promising candidate for a new type of therapy for neurodegenerative diseases. This is because it is involved in a variety of cellular processes that are involved in the development and progression of these diseases. By targeting ANGEL2 with drugs or other therapeutic agents, researchers may be able to slow the progression of neurodegenerative diseases and improve quality of life.

Current Treatments for Neurodegenerative Diseases

Current treatments for neurodegenerative diseases are limited and often have significant side effects. These treatments include medications that can slow the progression of the disease, such as Alzheimer's disease and Parkinson's disease. These medications can cause significant side effects, such as dizziness, drowsiness, and Restless Leg Syndrome. Additionally, these medications can cause changes in the brain that can make the disease worse.

Another approach to treating neurodegenerative diseases is to target specific proteins that are involved in the development and progression of these diseases. This is an approach that has been used to treat a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. For example, researchers have used antibodies to target and destroy specific proteins that are involved in the development and progression of these diseases.

NGEL2 as a Drug Target

NGEL2 has been identified as a potential drug target for neurodegenerative diseases because it is involved in the development and progression of these diseases. As mentioned earlier, studies have shown that ANGEL2 is involved in the development of neurodegeneration in models of Alzheimer's disease and Parkinson's disease. Additionally, ANGEL2 has been shown to be overexpressed in the brains of people with Alzheimer's disease, which may indicate that it is a potential drug target for this disease.

One way to target ANGEL2 with drugs is to use antibodies that are designed to block the activity of ANGEL2. This would involve using antibodies that are specific for ANGEL2 to target and destroy the protein in the cells. This approach has been used to treat a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

NGEL2 as a Biomarker

NGEL2 has also been suggested as a potential biomarker for neurodegenerative diseases because it is a protein that is expressed in many different tissues and cells in the body. This means that it may be a useful indicator of the presence of these diseases. For example, NGEL2 has

Protein Name: Angel Homolog 2

The "ANGEL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANGEL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets